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B I O P H Y S I C S
The use of nanovibration to discover specific 
and potent bioactive metabolites that stimulate 
osteogenic differentiation in mesenchymal stem cells
Tom Hodgkinson1,2, P. Monica Tsimbouri1, Virginia Llopis-Hernandez1, Paul Campsie3, 
David Scurr4, Peter G. Childs5, David Phillips6, Sam Donnelly1, Julia A. Wells7, Fergal J. O’Brien2, 
Manuel Salmeron-Sanchez5, Karl Burgess8, Morgan Alexander4, Massimo Vassalli5,  
Richard O. C. Oreffo7, Stuart Reid3, David J. France6, Matthew J. Dalby1*
Bioactive metabolites have wide-ranging biological activities and are a potential source of future research and 
therapeutic tools. Here, we use nanovibrational stimulation to induce osteogenic differentiation of mesenchymal 
stem cells, in the absence of off-target, nonosteogenic differentiation. We show that this differentiation method, 
which does not rely on the addition of exogenous growth factors to culture media, provides an artifact-free 
approach to identifying bioactive metabolites that specifically and potently induce osteogenesis. We first identify 
a highly specific metabolite, cholesterol sulfate, an endogenous steroid. Next, a screen of other small molecules 
with a similar steroid scaffold identified fludrocortisone acetate with both specific and highly potent osteogenic- 
inducing activity. Further, we implicate cytoskeletal contractility as a measure of osteogenic potency and cell 
stiffness as a measure of specificity. These findings demonstrate that physical principles can be used to identify 
bioactive metabolites and then enable optimization of metabolite potency can be optimized by examining 
structure- function relationships.
INTRODUCTION
Metabolites, the substrates and products of metabolism, are known 
to have wide-ranging functions in cells and organisms. In stem cell 
research, there is considerable interest in using metabolites as bio-
markers of growth and differentiation, for example, to provide mea-
surement of batch process in the manufacturing of cell therapies 
(1). However, there is emerging evidence that bioactive metabolites 
(which have biological activity and are also known as activity me-
tabolites) can be identified that drive and regulate cellular process-
es, such as differentiation (2–5). This is logical as metabolites feed 
into and contribute to a wide range of biochemical processes that 
can influence cell behaviors (6).
Bioactive metabolites have the potential to become important 
research tools that can be used to control the differentiation and 
activity of cells. For example, they could be used to stimulate stem 
cell differentiation, removing the need to use complex media for-
mulations, which often contain powerful growth factors or cortico-
steroids that can produce off-target and desired differentiations (2). 
We note that bioactive metabolites might also lend themselves to 
chemical modification to enhance their specificity and potency.
A critical tool in the discovery of candidate bioactive metabolites 
is development of methods that can control stem cell behaviors 
without changing media formulations. This is important as changing 
media to, for example, control differentiation program in one well, 
while maintaining phenotype in the control well will add artifact to 
metabolome surveillance (2). Thus, physical approaches, such as use 
of biomaterials or mechanical forces, will be important in identifi-
cation of bioactive metabolites.
We have previously developed a nanomechanical bioreactor that 
drives the differentiation of mesenchymal stem cells (MSCs) toward 
the osteogenic (bone) lineage in a highly specific manner (7). This 
bioreactor uses the reverse piezo effect to turn electrical input into 
mechanical movement, with piezo active ceramics placed under a 
ferrous actuating top plate. This top plate vibrates with a 60-nm 
peak-to-peak amplitude, which produces a 30-nm displacement of 
the plate at 1000 Hz. The bioreactor was developed in response to 
observations of cells vibrating their adhesions on the nanoscale (8) 
as a way to see whether vibrating the adhesive surface back at the 
cells could change phenotype. While fast, 1000-Hz, membrane vibra-
tions, termed flickering, are observed in erythrocytes, nucleated cell 
vibrations tend to be slower, in the 0.5 to 10 s of hertz range (9–12). 
Our optimal vibration of 1000 Hz is clearly substantially faster than 
this. However, it is known that hydrated collagen, as in the bone, 
requires kilohertz-range stimulus for piezoelectric effect to be 
observed (13) and that piezoelectricity in the bone can stimulate 
osteoblast activity (14).
We have used the bioreactor to differentiate MSCs in two- 
dimensional (2D) (15) and 3D (7) culture toward the osteogenic 
lineage without the use of specialized media; the cells are cultured in 
the same media as unstimulated controls. Typically, MSCs are stim-
ulated to undergo osteogenic differentiation through the use of os-
teogenic media (OGM), which contains a cocktail of dexamethasone 
(a corticosteroid), ascorbic acid, and glycerophosphate (16). However, 
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dexamethasone also drives MSCs to undergo adipogenic differenti-
ation (16) and thus acts in a nonspecific manner.
In this study, we demonstrate that the nanovibrational stimula-
tion of MSCs can be used to identify highly specific bioactive me-
tabolites that control MSC osteogenic differentiation. To achieve 
this, we used Stro1+ MSCs isolated from the human bone marrow 
(17). We note that the term “mesenchymal stem (stromal) cell” is 
now widely used and has come to often represent an adherent fibro-
blastic population of cells, even those that are not stem cells based 
on rigorous criteria (18). For avoidance of confusion, in this study, 
we use the term MSCs to refer to skeletal stem cells—a clonogenic 
population of nonhematopoietic bone marrow stromal cells that 
can recreate the cartilage, bone, hematopoiesis-supporting stroma, 
and marrow adipocytes on the basis of in vivo transplantation stud-
ies (18). We then used nanovibrational MSC culture and mass spec-
trometry to identify the endogenous steroid, cholesterol sulfate, 
as a specific osteoinducer. By then examining structure-function 
relationship between cholesterol sulfate and dexamethasone, we also 
showed that we could identify fludrocortisone acetate as being 
both a specific and highly potent osteoinducer. Our findings thus 
demonstrate how physical principles can be used to control cell re-
sponses and behaviors in discovery pipelines.
RESULTS
2D and 3D osteogenesis
Cell culture plates were firmly attached to the bioreactor (Fig. 1A) 
by magnets (Fig. 1B), enabling displacement to travel into the cell 
plates while allowing for their easy maintenance. To facilitate cali-
bration, we placed reflective strips into the bottom of the plates’ 
wells, which were used for 2D culture. For 3D cultures, we used type I 
collagen hydrogels (stiffness, 40 Pa; as measured by rheology) and 
placed the strip on top of the hydrogel (Fig. 1B and fig. S1). Thirty- 
nanometer displacements were measured using laser interferometry 
for both 2D and 3D conditions (Fig. 1C). We used collagen for our 
experiments as it has low stiffness, below the 30- to 40-kPa stiffness 
required to drive MSC osteogenesis (19, 20), and is biocompatible. 
It also sticks to the sides of the cell culture plates, providing mechani-
cal integration with the plate. As a hydrogel, it is also incompress-
ible (21), which means that it acts as a solid volume when vibrated 
in a contained environment, such as the wells of a culture plate; this 
provides good fidelity of vibration throughout its volume (7).
Before using this experimental setup to identify bioactive metab-
olites, we first checked that the nanovibrational stimulation (1000 Hz) 
of MSCs under 2D and 3D culture conditions specifically stimu-
lated osteogenesis. To do so, Stro-1–selected skeletal MSCs were seeded 
in 2D culture or within collagen gels for 3D culture and were nanovi-
brated for up to 28 days. The expression of an early osteogenic 
marker, runt-related transcription factor 2, (RUNX2), a mid-stage 
marker, osterix (OSX), and two late-stage osteogenic markers, oste-
opontin (OPN) and osteocalcin (OCN), was assessed by quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) and 
the expression profiles of stimulated cells (1000 Hz and OGM) 
normalized to those of unstimulated controls at day 0. The effect of 
culture on the expression of osteogenic markers in unstimulated MSCs 
was also assessed over 28 days and compared to 1000 Hz– and 
OGM-stimulated MSCs. MSCs cultured in either 2D or 3D and 
stimulated by 1000 Hz or by OGM produced similar patterns of 
osteogenic marker expression, with 3D culture conditions typically 
producing higher levels of osteospecific differentiation relative to 
2D conditions (Fig. 1D and fig. S2). Alkaline phosphatase (ALP) 
protein levels also showed a similar trend with both 1000-Hz and 
OGM stimulation enhancing osteoblastic differentiation (Fig. 1E). 
Using this same approach, we assessed the expression of adipo-
genesis [peroxisome proliferator–activated receptor  (PPAR)] and 
chondrogenesis [SRY-box transcription factor 9 (SOX9)] markers by 
qRT-PCR. In OGM-stimulated cultures, SOX9 was not expressed; 
however, we observed, as expected (16), increased PPAR expression 
under both 2D and 3D culture conditions (Fig. 1F). In 1000 Hz–
stimulated cultures, no evidence of off-target differentiation was 
observed (Fig. 1F), demonstrating that nanovibrational stimulation 
specifically stimulates osteogenic differentiation in the absence of 
defined media.
Surveying metabolic changes in OGM-treated 
and nanovibrated MSCs
We next used liquid chromatography–mass spectrometry (LC-MS) 
(22) to survey metabolic changes in MSCs cultured in 3D, as this 
culture condition is more physiological and produced the greatest 
changes in marker expression. We observed metabolite changes at 
days 7 and 14 of culture with or without nanostimulation and with 
OGM. We focused on the lipid compartment (Fig. 2, A and B) as 
the metabolite grouping with the most abundant change. Our data 
and principal components analyses showed that at day 7, the lipi-
domes of 1000 Hz–stimulated MSCs and of unstimulated day 0 and 
unstimulated day 7 controls were similar (Fig. 2A) but distinct along 
principal component 2 (Fig. 2B), while the lipidomes of OGM-treated 
MSCs showed large-scale changes. By day 14 of culture, both nanovi-
brated and OGM-stimulated MSCs had lipid trends that grouped 
together and that were divergent from unstimulated day 0 and un-
stimulated day 14 control cells (Fig. 2, A and B).
On the basis of our qRT-PCR data (see Fig. 1D), we selected day 
7 as the time point at which osteogenesis has been initiated (23, 24) 
and at which clear changes were evident in the metabolic profiles 
of nanovibration-stimulated versus OGM-stimulated cells. We used 
Ingenuity Pathway Analysis (IPA) to analyze the day 7 data to build 
predictive pathways linked to mitogen-activated protein kinase path-
ways, which are regularly linked to MSC osteogenesis, namely, extra-
cellular signal–regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal 
kinase (JNK) (25–28). This analysis showed that for both 1000 Hz– 
and OGM-stimulated cells, the metabolite expression pattern predicted 
an up-regulation of ERK1/2 (Fig. 2C). By contrast, the predictions 
for JNK were divergent. The metabolite expression pattern of 1000 Hz– 
stimulated cells predicted the up-regulation of JNK, while that of 
OGM-stimulated cells predicted JNK’s down-regulation (Fig. 2C). 
Together, these data indicate that metabolism differs between 1000 
Hz– and OGM-stimulated cells that are undergoing osteogenic dif-
ferentiation and that a more targeted differentiation can be achieved 
with nanostimulation.
Identification of activity metabolites
On the basis of our results, we hypothesized that we could identify 
bioactive metabolites with osteogenesis-inducing activity by look-
ing at day 7 mass spectrometry data because, at this time point, the 
metabolite changes in 1000 Hz–stimulated cells are likely to be 
linked to osteogenic differentiation. We also hypothesized that cor-
roborative changes present in the less-specific OGM data would point 
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commitment. To select metabolites, we looked for those that were 
depleted in 1000 Hz– and OGM-stimulated MSC cultures, relative 
to unstimulated day 0 and unstimulated day 7 control MSCs [raw 
data available at (29)]. In this way, we identified five candidate me-
tabolites, which were each tested for their ability to induce osteo-
genic marker gene expression by qRT-PCR at day 7 (RUNX2), day 
14 (ALP), and day 21 (OPN and OCN) culture with MSCs (at 1 M 
concentration; fig. S6) without nanovibrational stimulation. From 
these candidate bioactive metabolites, three were able to induce the 
increased expression of osteogenic markers when unstimulated, with 
cholesterol sulfate producing the most robust osteogenic response 
(Fig. 3A). Cholesterol sulfate is a cell membrane–associated sterol 
lipid that is considered to provide structural support but that is also 
a regulatory molecule associated with the transforming growth 
factor– (TGF) family (30, 31). Members of the TGF superfamily, 
such as bone morphogenetic protein 2 (BMP2), have known osteo-
genic properties (32–34).
Figure 3B shows the metabolite lipid compartment of MSCs af-
ter 7 days of 3D culture, and the depletion of cholesterol sulfate in 
1000 Hz– and OGM-stimulated MSCs compared to unstimulated 
day 7 and unstimulated day 0 controls. To probe the spatial distribu-
tion of cholesterol sulfate in cells, we turned to the recently reported 
mass spectrometry technique, 3D OrbiSIMS (35). This technique uses 
a hybrid mass spectrometer approach, comprising time-of-flight–
secondary ion mass spectrometry (TOF-SIMS) and orbitrap mass 
spectrometry. While TOF-SIMS rapidly gives spatial information, 
Fig. 1. Nanovibration drives osteogenic differentiation in 2D and 3D MSC cultures. (A) The nanovibrational bioreactor; cultureware is magnetically attached to a 
piezo-driven vibrational plate. (B) Cross-sectional drawing depicting 2D and 3D culture setups (3D culture; type I collagen gel; G′ ~ 13.7 Pa and E ~ 40 Pa). (C) Laser inter-
ferometry; mean vibration amplitude is within 2.5 nm of the 30-nm target (13 gels measured, n = 65 measurements). (D) Heatmap of osteogenic marker up-regulation in 
MSCs cultured over 28 days with nanovibration (1000 Hz) or OGM [quantitative reverse transcription polymerase chain reaction (qRT-PCR)], relative to day 0 and time-
matched unstimulated controls (d = 1, r = 4, and t = 3, where d is the number of donors, r is the number of replicate wells, and t is the technical replicates). (E) Alkaline 
phosphatase (ALP) activity assay showed significant increases in 1000-Hz and OGM groups, compared to unstimulated day 28 controls, d = 3, r = 2, and t = 3 (different 
colors indicate donors). (F) qRT-PCR of chondrogenic (SOX9) and adipogenic [peroxisome proliferator–activated receptor γ (PPARγ)] expression showed increased PPARγ 
expression in OGM groups compared to unstimulated day 0 controls, d = 3, r = 3, and t = 3 (different shapes indicate donors). Significance values calculated using Kruskal- 
Wallis with Dunn’s multiple comparison test. All results are means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001. Larger versions of (E) and (F) are available in fig. S3. Pho-
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Fig. 2. Metabolic profiles of MSCs in 3D culture for 7 days with OGM or nanovibration. (A) Heatmap (red, up-regulations; blue, down-regulations) and (B) principal components 
(PC) analysis depicting differences in nanovibration and OGM metabolic profiles during MSC differentiation. Metabolic profiles of MSCs induced by nanovibrational stimulation show 
a greater similarity to unstimulated controls at day 7 (d7) of culture and to OGM-stimulated cells at day 14 (d14). (C) Metabolic profiles were compared by Ingenuity Pathway 
Analysis (IPA). The analysis uses a curated literature database to plot metabolite interactions linked to abundance (red, increased measurement; green, decreased measure-
ment). Further, it links groups of metabolites to biochemical pathways, such as extracellular signal–related kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), predicting path-
way up-regulation and down-regulation (orange, predicted activation; blue, predicted inhibition). The metabolic profiles of nanovibrated cells lead to stronger predicted 
activation of ERK1/2 relative to the metabolic profiles of cells induced by OGM. In contrast, the metabolic profiles of OGM-stimulated cells lead to stronger predicted down-regulation of JNK, 
while those of nanovibrated cells predict JNK’s activation rather than inhibition. Networks are built from d = 1 and r = 4. ACAC, acetyl-CoA carboxylase alpha; ADP, adenosine 
5’-diphosphate; Asc, Apoptosis-associated speck-like protein containing a CARD; Casp1, caspase 1; C/EBP, CCAAT/enhancer binding protein; Ces, carboxylesterase; Cpla2, 
Cytosolic phospholipases A 2; 15(S)-HETE,15-Hydroxyeicosatetraenoic acid; Hsp27, Heat shock protein 27; Ldh, lactate dehydrogenase; Ikb, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor; IKK, inhibitor of nuclear factor κB kinase.; NADPH, reduced form of nicotinamideadenine dinucleotide phosphate; Nalp3, 
NLR family pyrin domain containing 3; Pmca, plasma membrane Ca2+ ATPase; P2y, purinoceptor; Rsk, ribosomal s6 kinase; Sod, superoxide dismutase; TH2, Type 2 helper 
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Fig. 3. Screening metabolites for osteogenic bioactivity in MSCs. (A) Differential osteogenic gene expression [RUNX2 (day 7), ALP (day 14), and OPN/OCN (day 21)] in MSCs 
supplemented with metabolites depleted during OGM and nanovibration osteogenic differentiation, 1 M cholesterol sulfate up-regulated late-stage markers, ALP and 
OCN. Means ± SEM, versus unstimulated time-matched controls, d = 1, r = 3, and t = 3. Chol, cholesterol sulfate; l-Orn, l-ornithine monohydrochloride; Iso A, isonicotinic ace-
tate; 1-Palm, 1-palmitoyl-sn-glycero-3-phosphocholine; SGH, sodium glycocholate hydrate; DMSO, dimethyl sulfoxide control. (B) Heatmap comparing MSC lipid metabolism 
(columns indicate means; d = 1 and r = 4). OGM and nanovibration osteogenic differentiation depleted cholesterol sulfate. Means ± SEM, d = 1, r = 3, and t = 3. ac, acid; FA, fatty acid; 
PR, prenol lipid. (C) OrbiSIMS image of cholesterol sulfate within MSCs, d = 1, r = 3, and t = 3. MSC stiffness (Young’s modulus, nanoindentation). Chol S1 and Chol S2 indicate 1 
and 2 M cholesterol sulfate, respectively. Cholesterol sulfate reduces cortical and bulk cell stiffness, d = 2, r = 2, and t ≥ 100; colors denote donors, and lines denote means (arrows in-
dicate control mean). In-cell Western of p-myosin/total myosin. Cholesterol sulfate reduced intracellular tension, means ±SD, d = 1, r = 4, and t = 1. (D) Molecular structures of selected 
molecules combining elements of cholesterol sulfate and dexamethasone. (A and C) Kruskal-Wallis with Dunn’s multiple comparison test. (B) One-way analysis of variance (ANOVA) 
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Fig. 4. Screening cholesterol sulfate analogs for osteogenic bioactivity in MSCs. (A) alamarBlue analysis of MSC metabolic viability with selected steroid supplemen-
tation at 1 M. Results are means ± SEM, d = 2, r = 2, and t = 3, one-way ANOVA with Geisser-Greenhouse correction and Tukey multiple comparison test. (B) qRT-PCR 
comparing osteogenic gene expression in MSCs stimulated with metabolite analogs (1 M) for 21 days. Fludrocortisone acetate induced osteogenesis at levels similar to 
OGM. Results are means ± SEM compared to unstimulated day 21 controls, d = 4, r = 3, t = 3; different colors indicate donors, dots indicate individual values, and trian-
gles indicate means; Brown-Forsythe and Welch ANOVA. *P < 0.05 and **P < 0.01. (C) Adipogenic (PPAR) and chondrogenic (SOX9) gene expression after 21 days (qRT-
PCR) (left). DEX (OGM), (+)-4-cholesten-3-one, and triamcinolone induced adipogenic differentiation. Results are means ± SEM compared to unstimulated day 21 MSCs, 
d = 4, r = 3, and t = 3, Brown-Forsythe and Welch ANOVA. *P < 0.05 and **P < 0.01. Right, Oil Red O staining of lipid vesicles observed in (+)-4-cholesten-3-one–, triamcinolone-, 
and OGM-stimulated MSCs. (D) Specificity versus potency plot of bioactive metabolites. On the basis of osteogenic, adipogenic, and chondrogenic gene expression, dif-
ferentiation potency was scored out of 5. Fludrocortisone acetate scored highly for potency and specificity (arrows denote fludrocortisone acetate, and asterisks denote 
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orbitrap provides accurate small-molecule detection at specific lo-
cations. Using this technique, we observed cholesterol sulfate to be 
localized within cells fed with cholesterol sulfate–supplemented 
media, after 72 hours of culture (Fig. 3C and fig. S7). As cholesterol 
sulfate is membrane associated and was retained in cells, we hy-
pothesized that it would alter the stiffness of the MSCs. Using 
nanoindentation to assay cell mechanics, we observed a significant 
decrease in Young’s modulus (E) in both the cell cortical region 
(first 270 nm) and the bulk cell (first 670 nm) (Fig. 3C). This indi-
cated that cholesterol sulfate decreases cell stiffness.
We next assessed phosphorylated myosin (p-myosin), specifi-
cally pSer19, as Rho-associated protein kinase, which is involved in 
cytoskeletal contraction (36), phosphorylates myosin at this posi-
tion. In cholesterol sulfate–treated cells, we observed that while OGM 
treatment increased MSC cytoskeletal tension, cholesterol sulfate 
treatment did not cause any change from control (Fig. 3C). By ob-
serving fluorescently stained actin in MSCs treated with cholesterol 
sulfate, we found these cells to have similar actin stress fiber organi-
zation to control, while, again, OGM-treated cells displayed more 
prominent stress fibers indicative of increased cytoskeletal tension 
(fig. S8).
Although the specificity of cholesterol sulfate for osteogenic dif-
ferentiation was high, we were curious to see whether the potency of 
this effect could be improved. The widespread use of the synthetic 
glucocorticoid dexamethasone to induce differentiation (37), com-
bined with our observation that cholesterol sulfate (30, 31) also in-
duces osteogenesis in MSCs, prompted us to focus on the steroid 
scaffold. We therefore looked for molecular structures of small mol-
ecules that combined structural elements of cholesterol sulfate and 
dexamethasone and screened those that did in MSCs. To do so, we 
Fig. 5. Dexamethasone and fludrocortisone acetate exhibit different osteogenic activities. (A) Effects of glucocorticoid (mifepristone) and mineralocorticoid inhibi-
tion (canrenone) on top-ranked metabolite-driven biochemical networks. IPA predicts ERK1/2 activation with OGM and fludrocortisone acetate and ERK1/2 hub 
down-regulation with glucocorticoid inhibition. Mineralocorticoid inhibition caused no change in predicted ERK1/2 activity. Results are means, d = 1 and r = 4. (B) Gluco-
corticoid inhibition resulted in few osteogenic marker changes in unstimulated day 21 controls. OGM up-regulated all tested markers with mifepristone. Fludrocortisone 
acetate down-regulated most osteogenic markers with mifepristone. Results are means, d = 1, r = 4, and t = 2, Mann-Whitney t test. (C) 3D OrbiSIMS of putative breakdown 
products, showing several unique to fludrocortisone acetate (d = 1 and r = 3). (D) MSC stiffness (Young’s modulus, nanoindentation) in control, OGM, and fludrocortisone 
acetate groups. Fludrocortisone acetate reduces cell stiffness, d = 2, r = 2, and t ≥100; colors indicate donors, dashed lines indicate means; Kruskal-Wallis with Dunn’s 
multiple comparison test, significance versus control unless denoted (arrows denote control mean). Analysis of p-myosin/total myosin shows increased intracellular 
tension with OGM and fludrocortisone acetate treatment compared to unstimulated control. Results are means ± SD, d = 1 and r = 6; Kruskal-Wallis with Dunn’s multiple 
comparison test. Fluorescent actin images of control and fludrocortisone acetate MSCs. More organized stress fibers were observed with fludrocortisone acetate versus 
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elected to screen a library of natural and synthetic steroids (Fig. 3D) 
to see whether we could improve on the potency and specificity of 
cholesterol sulfate response.
Fludrocortisone acetate shows enhanced potency 
and specificity
As a first step, we assessed whether the candidate molecules we 
selected in our screen affected MSC viability. We observed no 
difference in cell viability between treated cells and unstimulated 
controls over 2 weeks of culture (Fig. 4A). Next, we performed qRT-
PCR to assess the expression of osteogenic markers (RUNX2, ALP, 
and OPN; Fig. 4B) and of two off-target adipogenic (PPAR) and 
chondrogenic (SOX9) markers. Several small molecules, most nota-
bly fludrocortisone acetate, robustly induced osteogenesis without 
inducing adipogenesis or chondrogenesis. By contrast, dexamethasone- 
containing OGM induced both osteogenesis and adipogenesis, as 
did (+)-4-cholesten-3-one and triamcinolone, indicating their lack 
of specificity. This off-target induction of adipogenesis was visible 
in treated cells in the form of accumulating lipid droplets, which 
were stained by Oil Red O, identifying them as mature adipocytes 
(Fig.  4C). It is notable that while no candidate molecule induced 
chondrogenesis, a number, including fludrocortisone acetate, re-
duced SOX9 expression (Fig. 4C).
To ensure specificity, we checked the candidate molecules with a 
nonosteogenic, fibroblast cell line. Looking at transcripts of RUNX2, 
OPN, OCN, ALP, SOX9, and PPAR as a panel of osteogenic and 
other mesenchymal markers, it was seen that all candidate molecules 
gave no response in the fibroblasts except for fludrocortisone (noting 
that fludrocortisone acetate gave no change) and dexamethasone- 
containing OGM that both up-regulated ALP (fig. S9). Dexamethasone 
has been implicated in increasing ALP expression in fibroblasts (38), 
again demonstrating the general rather than specific nature of this 
potent glucocorticoid.
Potency/specificity plots for osteogenesis versus adipogenesis 
(Fig.  4D) and for osteogenesis versus chondrogenesis (Fig.  4E) 
show that OGM has high potency but low specificity, while choles-
terol sulfate has good potency and high specificity. The synthetic 
mineralocorticoid, fludrocortisone acetate, however, demonstrated 
both high potency and high specificity. Protein-level quantitative 
and qualitative data on the osteogenic potency of the candidate 
small molecules are provided in fig. S10 and show that fludrocorti-
sone acetate produced high levels of osteogenic marker expression 
and matrix mineralization.
Although fludrocortisone acetate is known primarily as a miner-
alocorticoid, it also has a pronounced glucocorticoid effect, approxi-
mately one-third that of the widely used glucocorticoid, dexamethasone 
(39, 40). However, little information is available on its osteogenic 
potential, although a previous small-molecule screen did identify 
fludrocortisone acetate as a hit for osteoinduction but provided no 
insight on its specificity or mechanism (41).
Fludrocortisone acetate and dexamethasone act differently
Next, we treated MSCs with inhibitors of glucocorticoids (mifepri-
stone, also known as RU-486) and mineralocorticoids (canrenone) 
and performed untargeted metabolomic screens after 7 days of cul-
ture with either OGM or fludrocortisone acetate. The resulting data 
were analyzed by IPA and were compared to control data, with the 
activity predictor tool enabled to providing biochemical hub infor-
mation. In the top-ranked network results, around ERK1/2 [which 
is known to be critical for initiating osteogenesis (25–28)], little dif-
ference was seen between cells cultured in dexamethasone-containing 
OGM and fludrocortisone acetate (Fig. 5A). Under both OGM 
and fludrocortisone acetate conditions, MSCs were predicted to 
up-regulate the ERK1/2 pathway, as expected, in agreement with the OGM 
and nanovibrational data reported in Fig. 2C. Glucocorticoid signaling 
inhibition was predicted to lead to the down-regulation of ERK1/2, 
indicating that the glucocorticoid activity of dexamethasone and of 
fludrocortisone acetate is likely contributing to their actions. Min-
eralocorticoid signaling inhibition produced no change in predicted 
ERK1/2 activity, compared to standard conditions without the inhibitor. 
This indicates that mineralocorticoid activity is not a driving factor.
Following these results, we cultured MSCs for 3 weeks with 
mifepristone and assayed for osteogenic marker expression with 
qRT-PCR (Fig. 5B). Subtle changes in marker expression were ob-
served in treated control cells, while in OGM- and fludrocortisone 
acetate–stimulated MSCs, large effects were seen on each tested 
marker’s expression in the presence of glucocorticoid signaling in-
hibition. In cells cultured with OGM, glucocorticoid signaling inhi-
bition up-regulated osteogenic marker expression. For cells cultured 
with fludrocortisone acetate, the opposite was true, and inhibition 
caused the markers’ down-regulation. We speculate that could be 
because the very high glucocorticoid activity of dexamethasone in-
hibits its full potential in terms of osteogenesis.
As before, we used 3D OrbiSIMS to investigate the location of 
fludrocortisone acetate and dexamethasone in the cells. Unlike cho-
lesterol sulfate, neither were identified as remaining in the cells 
after 3 days of culture (fig. S11). However, fludrocortisone acetate 
appears to be metabolized quite differently to dexamethasone, with 
a range of distinctive chemical signatures being noted following 
fludrocortisone acetate stimulation (Fig. 5C).
We measured Young’s modulus (E) of MSCs under control, 
OGM-, and fludrocortisone acetate–containing conditions and 
observed a reduction in cortical and bulk E, but only for fludro-
cortisone acetate–treated cells (Fig. 5D). The difference, howev-
er, for fludrocortisone acetate was not as great as that seen with 
cholesterol sulfate (Fig. 3C). However, intracellular tension and 
actin cytoskeletal organization were increased in fludrocortisone 
acetate– and OGM-treated MSCs compared to control (Fig. 5D 
and fig. S7). It is interesting that fludrocortisone acetate–treated 
MSCs are less stiff, similarly to cholesterol sulfate–treated 
cells, while cytoskeletal tension is increased, more similarly to 
dexamethasone-treated cells.
DISCUSSION
Our results show that nanovibrational stimulation can be used to 
identify bioactive metabolites that induce the highly specific osteo-
genic differentiation of MSCs. The specificity with which osteogenic 
differentiation is induced is important for overcoming the artifacts 
caused by using soluble factors, such as dexamethasone (16) and 
BMP2, which induce the differentiation of other lineages, in addi-
tion to osteogenesis (42, 43). Had we used dexamethasone to induce 
osteogenesis in MSC culture, rather than nanovibration, our data 
show that we would have likely generated many false-positive hits 
in the metabolome analysis, since many off-target metabolites were 
differentially regulated.
We also demonstrate that identified bioactive metabolites can 
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show that the small molecule, fludrocortisone acetate, which shares 
structural similarities to the bioactive metabolite we identify here as 
having osteogenesis-inducing properties, cholesterol sulfate, induc-
es highly specific osteogenic differentiation but with greater poten-
cy relative to the activities of cholesterol sulfate and dexamethasone. 
Fludrocortisone acetate–treated MSCs responded similarly to dexa-
methasone-treated MSCs, in that both compounds were metabo-
lized rather than retained. However, fludrocortisone acetate– and 
dexamethasone-treated MSCs showed different glucocorticoid 
activities and metabolized each compound differently, as moni-
tored by 3D OrbiSIMS. Fludrocortisone acetate also produced 
similar effects as cholesterol sulfate in terms of the mechanical prop-
erties of the cells.
The cytoskeleton/cell stiffness data are interesting as it gives 
similarities between dexamethasone and fludrocortisone acetate in 
terms of increased cytoskeletal tension and then it gives similarities 
between cholesterol sulfate and fludrocortisone acetate in terms of 
decreased cell stiffness. Within the literature are publications that 
show decreasing cell stiffness with osteocommitment (44, 45). In these 
reports, osteogenesis is initiated using dexamethasone (44, 45), which, 
while always showing a trend of decreasing stiffness, did not greatly 
lower osteoblast cortical or bulk stiffness in our study. A hypothesis 
we can allude to from the literature is that typically MSCs have more, 
but smaller, adhesions than osteoblasts (46) and, in MSCs, the cell 
membrane is more tethered to adhesions reflecting that MSCs need 
to respond to environmental cues (45). Osteoblasts, on the other 
hand, in common with other connective tissue cells, are required 
to withstand the loads mechanical strain places on tissues and so 
tether the membrane to linker complexes such as the ERM proteins 
(ezrin, radixin, and moesin) (45). We have previously reported in-
creased expression of ezrin with onset of MSC osteogenesis (47), 
and other studies have shown that ERM depletion leads to inability 
to chemically induce osteogenesis (48). Thus, while it may seem coun-
terintuitive that MSCs soften as they increase intracellular tension 
to commit to osteogenesis (as we see with p-myosin), how adhesions 
and the cytoskeleton interact with the membrane may change to give 
physiological advantage, and significant softening of the cells could 
be a useful indicator of specific osteoinducers. In parallel, observa-
tion of increased cytoskeletal tension is required to identify potent 
osteoinducers. This second measure is important as it appears that 
cholesterol sulfate was a less potent osteoinducer than fludrocorti-
sone acetate as, while it affected membrane stiffness, it did not in-
crease cytoskeletal tension.
Note that while cortical stiffness may decrease with osteocom-
mitment, membrane attachment strength increases. A report that 
studied membrane properties using micropipette aspiration to mea-
sure the critical pressure required for membrane detachment and 
blebbing during chondrogenic differentiation of MSCs noted in-
creased ERM expression was directly proportional to increased criti-
cal pressure (49).
That there are differences in metabolism of cholesterol sulfate, 
dexamethasone, and fludrocortisone acetate is clear. However, 
understanding target and mechanism will be more challenging. 
Looking at flux using heavy-labeled isotopes (50) and using, for 
example, chemical proteomics (51) where the metabolite is immo-
bilized to a bead and then exposed to cell lysate before mass spec-
trometry could be sensible next steps.
Note that our activity metabolite testing data have been per-
formed on cells in 2D, and there will be differences when scaled to 
3D. For nanovibrational MSC stimulation, there are similarities in 
known mechanism in 2D and 3D in that intracellular tension from 
adhesion and mechanoresponsive channels (e.g., transient receptor 
potential cation and piezo channels) have been identified under 
both conditions (7, 15, 52). However, in 2D, the bias appears to be 
toward adhesion and tension regulation of MSC osteogenesis, and 
in 3D, the bias is toward mechanoresponsive channel regulation 
(7, 15, 52). In the future, it will be interesting to see how these bio-
active metabolites influence 3D and 2D cell microenvironments.
By further researching mechanism, the potential to develop new 
drugs from bioactive metabolites will increase through develop-
ment of simple in vitro assays. Here, we show ability to select highly 
specific candidates and then tune potency compared to use of stan-
dard protocols. Further, we demonstrate that stiffness and cell ten-
sion give good indication of specificity and potency.
Reducing the rate of false-positive results is of critical importance 
for drug discovery pipelines. Although genomic/high-throughput 
technology has led to a volume-based research approach, productivity 
has remained static (53). For example, from 2011 to 2016, only 66% 
of small-molecule projects failed, and critically, only 23% failed be-
fore clinical trial (i.e., were “cheap fails”) (53). Thus, too many leads 
make it to trial, and this is largely linked to the use of cell culture 
models that are not predictive ahead of reliance on nonhuman in vivo 
models (54). Providing more stringent selectivity for the leads en-
tering the pipeline would thus represent a large advantage. We note 
that we provide proof of concept in MSCs, but this could just as well 
apply to other stem cell or fastidious cell types.
The candidate small molecule, fludrocortisone acetate, that we 
identify here is interesting as it is already used as a drug to treat adreno-
genital syndrome, postural hypotension, and adrenal insufficiency 
(55). This means that the use for control of stem cells in, for exam-
ple, osteoporosis could represent a repurposing and thus a simpler 
regulatory route.
Our work strongly advocates for the use of physical principles to 
control biology in discovery pipelines. As demonstrated here, ap-
proaches such as the use of nanovibrational stimulation can be more 
specific and more potent than traditional approaches and thus en-
able identification of highly bioactive metabolites. With a growing 
physical science toolbox (bioreactors, materials, nanoparticles, etc.) 
available to researchers, the potential for novel methods for enabling 
metabolite-based drug discovery is huge.
MATERIALS AND METHODS
Nanovibrational apparatus
The design of the nanovibrational bioreactor has been previously 
described (7). Briefly, standard cell culture plates (Corning, NY) were 
magnetically attached (NeoFlex Flexible Neodymium Magnetic Sheet, 
3M, MN, USA) to the vibration plate (dimensions, 128 mm by 
176 mm). The vibration plate was secured on its underside to an 
array of low-profile, multilayer piezo actuators (NAC2022, Noliac 
A/S CTS, Denmark). To power the piezo array, a custom power 
supply unit was used, as detailed in a previous publication (56), 
consisting of a signal generator integrated circuit (AD9833, Analog 
Devices, MA, USA) to provide a 1000-Hz sine wave modulation. A 
parallel configuration of class AB audio amplifiers (TDA7293, 
STMicroelectronics, Geneva, Switzerland) was used to amplify the 
sine wave signal. This results in the vibration plate oscillating at an 
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Interferometric measurement
Vibrational amplitude was measured using a laser interferometry 
system previously used to accurately measure nanoscale displace-
ments generated by the bioreactor platform used here (7, 56). A USB 
interferometer (Model SP-S, SIOS Messtechnik GmbH, Ilmenau, 
Germany) was mounted on a frame, with the laser aimed downward 
at the measurement site. To measure displacement in 2D cultures, 
self-adhesive reflective tape was stuck to measurement sites on plas-
tic culture plates to reflect the laser for accuracy. Similarly, to mea-
sure displacement in 3D cultures, prismatic tape was adhered to the 
surface of type I collagen gels. The analysis of the interference pat-
tern between the reflected laser light and the reference signal in the 
interferometer’s INFAS software (where the time series interference 
signal is converted to frequency space by fast Fourier transform) al-
lowed the displacement of the target surface to be determined from 
the produced frequency spectrum. This model of interferometer is 
sensitive to displacements of 0.1 nm. However, seismic noise (pro-
duced by people walking and moving around near the apparatus) 
can reduce this sensitivity. To prevent this noise from affecting the 
measurements, the interferometric apparatus was mounted on an 
optical bench supported by polystyrene blocks to provide noise 
dampening. For 2D and 3D comparisons of nanovibrational ampli-
tude, 65 measurements were taken at multiple locations on the plates.
Rheology measurements
Rheological measurements were carried out using an Anton Paar 
301 rheometer. Strain sweeps were carried out using a parallel plate 
system with a 25-mm sand-blasted plate and a gap of 2.8 mm. Two- 
milliliter collagen gels were prepared beforehand in a 12-well plate 
and then transferred to the rheometer plate for measuring. Strain 
sweep tests were performed at an angular frequency of 10 rad s−1 and 
a strain of 0.1 to 5000%. All experiments were performed at 25°C.
Calculation of Young’s modulus
An average of the storage shear modulus was taken within the vis-
coelastic region (0.1 to 10% strain) giving 13.7 Pa. Collagen gels are 
homogeneous and isotropic from the mechanical point of view, and 
a reference estimate for the Young’s modulus in the linear region can 
be obtained from the shear measurements using the following equation
  G ′ =  E′ ─ 2(1 + v)
where G′ is the storage shear modulus, v is the Poisson’s ratio, and 
E′ is the Young’s modulus. Assuming full incompressibility for the 
material (Poisson’s ratio, 0.5), this gives a value of 41.7 Pa for the 
Young’s modulus
  G * =  E ─ 2(1 + v)
At ~200% strain, some slipping was observed, and this explains 
the increased size of the error bars in the region beyond this point.
Application of nanovibration in 2D and 3D culture
Stro1+ MSCs were isolated from the human bone marrow (10). MSCs 
were cultured in expansion media {Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma-Aldrich), 10% fetal bovine serum (FBS; 
Sigma-Aldrich), 1% sodium pyruvate (11 mg ml−1; Sigma-Aldrich), 
1% Gibco MEM nonessential amino acids (Thermo Fisher Scientific), 
2% antibiotics [penicillin-streptomycin (6.74 U  ml−1; Sigma-Aldrich) 
and fungizone (0.2 g ml−1; Sigma-Aldrich)]} or in osteogenic 
differentiation media [OGM; DMEM expansion media, supple-
mented with 100-mol ascorbic acid (Sigma-Aldrich), 100-nmol 
dexamethasone (Sigma-Aldrich), and 10-mmol glycerol phosphate 
(Sigma-Aldrich)]. Nanovibration (30-nm displacement; 1000 Hz) 
was applied to MSCs in 2D and 3D culture. Nanovibrated cell re-
sponses were compared to those of unstimulated control MSCs cultured 
in expansion media and to those of MSCs cultured in osteogenic 
differentiation media without nanovibration.
In 2D culture, cells were seeded at 4 × 103 cells cm−2 in standard 
cell culture plates in either expansion or OGM. For 3D culture, 
type I collagen gel was prepared by the addition of 10× DMEM 
(Sigma-Aldrich), FBS, expansion media, and rat-tail type I collagen 
(2.05 mg ml−1; First Link) in 0.16% acetic acid. The pH of the col-
lagen solution was neutralized through the addition of 0.1 M 
NaOH on ice until a constant pH 7 was reached. The appropriate num-
ber of MSCs was then added to give a cell density of 4 × 104 cells 
ml−1, and the solution was mixed by pipette to provide a homogenous 
cell suspension. Solutions were pipetted into culture 24-well plates 
(1 ml of gel/cell solution giving a depth of 5.2 mm) and allowed 
to gel in humidified incubators [37°C and 5% (v/v) CO2] for 2 hours. 
Subsequently, wells were flooded with the relevant media. Plates con-
taining cells for nanovibration were then magnetically attached to 
the nanovibration bioreactor in cell culture incubators.
Effect of nanovibration or OGM on MSC differentiation
To compare the effects of nanovibration or OGM on MSC osteo-
genic differentiation, cells were seeded as above under 2D and 3D 
culture conditions. Over a 28-day time course, cells were stimulated 
continuously either with nanovibration (30 nm/1000 Hz) or with 
OGM or were left unstimulated, as controls. Samples were taken for 
qRT-PCR at days 0, 7, 10, 14, 21, and 28 to determine changes in the 
expression of early (RUNX2; OSX) and late (OPN; OCN) osteogenic 
marker genes. To analyze off-target gene expression, the expression 
of adipogenesis (PPAR) and chondrogenesis (SOX9) markers was 
also analyzed by qRT-PCR.
Quantitative reverse transcription polymerase 
chain reaction
RNA was extracted from 2D and 3D cultures through TRIzol ex-
traction (Life Technologies). Media were removed, and cells were 
washed in sterile phosphate-buffered saline (PBS) on ice. Equal 
volumes of TRIzol reagent were added to cells, and cells were incu-
bated for 10 min at room temperature. TRIzol was transferred to 
1.5-ml tubes, and 0.2 ml of chloroform was added to each tube per 
1 ml of TRIzol. TRIzol/chloroform solutions were vortexed and cen-
trifuged (13,000g/4°C). Following centrifugation, the upper aqueous 
layer was transferred to a new 1.5-ml tube and an equal volume of 
70% (v/v) ethanol added. This solution was mixed by repeated 
inversion of the tubes. RNA was then extracted from this solution 
using the QIAGEN RNeasy Extraction Kit (including deoxyribonu-
clease step), according to the manufacturer’s instructions. RNA was 
eluted in nuclease-free water and quantified using the NanoDrop 
and normalized across all samples. Complementary DNA (cDNA) 
(1000 ng per sample) was prepared by reverse transcription using 
the QIAGEN QuantiTect Kit, according to the manufacturer’s 
instructions. cDNA concentration was normalized to 5 ng l−1 by 
dilution in nuclease-free water. Using the 7500 real-time PCR sys-
tem from Applied Biosystems, qRT-PCR was performed using the 
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human gene target primers (Eurofins Genomics) (Table 1 and fur-
ther information in table S1), validated by dissociation/melt curve 
analysis. Ten nanograms of cDNA was loaded into each qRT-PCR 
reaction. qRT-PCR products were quantified using the 2−Ct method 
(57) and normalized to the housekeeping gene glyceraldehyde- 
3-phosphate dehydrogenase (GAPDH), which was confirmed to 
remain stable under all culture conditions.
ALP activity assay
To assess ALP activity in cultured cells, a colorimetric assay was 
used (ab8369, Abcam). This kit uses p-nitrophyenyl phosphate 
(pNPP) as a phosphatase substrate that turns yellow [maximum opti-
cal density (ODmax), 405 nm] when dephosphorylated by ALP. Increased 
ALP activity in cultured MSCs was indicative of the formation of 
osteogenic cell phenotypes. The assay was performed according to the 
manufacturer’s instructions. Briefly, cells were trypsinized, counted, 
pelleted, and washed in ice-cold PBS. Cells were then resuspended 
in 50-l assay buffer per 1 × 105 cells, then homogenized on ice, and 
centrifuged at 13,000g for 15  min at 4°C. The supernatant was 
transferred to a new tube. Supernatant volume to be added was 
optimized on the basis of standard curve concentrations, and the 
reaction volume was adjusted to 80 l per well. Fifty microliters of 
5 nM pNPP solution was added to each well and incubated at 
25°C for 60 min protected from light. Stop solution was then added 
to each well, and an OD of 405 nm was measured on a microplate 
reader. Corrected mean absorbance values were calculated by 
subtracting blank readings, and ALP activity was determined by 
applying the generated standard curve and using the follow-
ing equation
  ALP activity (mol / min / ml or U / ml ) = (B / T * V ) * D 
where B is the amount of pNPP in sample well calculated from stan-
dard curve (in micromoles), T is the reaction time (in minutes), V is 
the original reaction sample volume (in milliliters), and D  is the 
sample dilution factor.
Metabolomics
MSCs were stimulated with nanovibration for 7 and 14 days in 2D 
and 3D (collagen gels; 2 mg ml−1) culture. Nonstimulated samples 
cultured in expansion media and OGM were used as controls. Me-
tabolites were extracted using a 1:3:1 chloroform/methanol/water 
extraction buffer and vigorously shaken at 4°C for 1 hour. Follow-
ing this, metabolite extraction solution was collected, transferred to 
1.5-ml tubes, and centrifuged for 3 min at 13,000g at 4°C. Metabo-
lomics was performed through hydrophilic interaction LC-MS analysis 
(UltiMate 3000 RSLC, Thermo Fisher Scientific) with a 150 mm by 
4.6 mm ZIC-pHILIC column running at 300 l min−1and Orbitrap 
Exactive (Thermo Fisher Scientific). A standard pipeline, consisting 
of XCMS (58) (peak picking), MzMatch (59) (filtering and grouping), 
and IDEOM (60) (further filtering, postprocessing, and identifica-
tion), was used to process the raw mass spectrometry data. Identi-
fied core metabolites were validated against a panel of unambiguous 
standards by mass and retention time. Further putative identifica-
tions were allotted mass and predicted retention time (22). Means 
and SEs of the mean were generated for every group of picked peaks, 
and the resulting metabolomics data were uploaded to IPA software 
for pathway analysis.
Chemistry
Dexamethasone, cholesterol sulfate, fludrocortisone, fludrocortisone 
acetate, triamcinolone, cholic acid, and (+)-4-cholesten-3-one 
were obtained from commercial suppliers and used as received. 
Cholesta-1,4-dien-3-one that was prepared according to a literature 
procedure on related steroids (61) to a solution of (+)-4-cholesten-
3-one (100 mg, 0.26 mmol) in dioxane (1.6 ml) was added tert- 
butyldimethylsilyl chloride (2.0 mg, 0.013 mmol), and then the 
mixture was cooled to 0°C. To the solidified solution, DDQ was 
added (66 mg, 0.29 mmol). The mixture was allowed to warm to room 
temperature and then stirred for 3 days. The solvent was removed in 
vacuo and the residue dissolved in CH2Cl2 (40 ml) and then washed 
with saturated aqueous Na2S2O3 (40 ml), NaHCO3 (40 ml), and brine 
(40 ml). The organic phase was dried over Na2SO4, filtered, and concen-
trated in vacuo to give a yellow oil. Purification by flash chromatography 
(petroleum ether/ethyl acetate, 9:1) afforded the title compound as 
a white solid (33 mg, 33%). Analytical data (fig. S12) were in accor-
dance with literature values (62). 1H nuclear magnetic resonance 
(400 MHz, CDCl3) : 7.05 parts per million (ppm) (1H, d, J = 10.1 Hz), 
6.22 ppm (1H, dd, J = 10.1, 1.9 Hz), 6.06 ppm (1H, s), 2.50 to 2.42 ppm 
(1H, m), 2.37 to 2.32 ppm (1H, m), 2.06 to 2.01 ppm (1H, m), 1.96 
to 1.79 ppm (2H, m), 1.69 to 1.46 ppm (6H, m), 1.36 to 1.26 ppm (4H, m), 
1.23 ppm (3H, s), 1.20 to 0.97 ppm (9H, m), 0.90 ppm (3H, d, 
J = 6.5 Hz), 0.86 ppm (6H, dd, J = 6.6, 1.8 Hz), and 0.74 ppm (3H, s).
Culture with cholesterol sulfate and selected compounds
To assess the bioactivity of the steroid library, MSCs were seeded at 
4 × 103 cells cm−2 in standard cell culture plates and allowed to attach 
overnight [37°C and 5% (v/v) CO2]. Media were then exchanged for 
media supplemented with the relevant small molecule at 0.1, 1, or 
10 M. Concentration were selected for bioactivity screening by 
qRT-PCR after 21 days of culture by assessing RUNX2 expression. 
Through this, 1 M concentrations were selected for further exper-
imental comparisons in culture time courses of up to 21 days. The 
relevant compound was supplemented to control expansion media 
before media changes, which were performed every other day.
alamarBlue assay
At determined intervals during culture, cell culture media were re-
moved, and cells washed with prewarmed, sterile PBS. alamarBlue 
resazurin (10%, v/v; Bio-Rad) was diluted in phenol-red free media 
(D5030, Sigma-Aldrich) and added to each hydrogel. Cells were in-
cubated in alamarBlue working solution for 4 hours [at 37°C and 
5% (v/v) CO2]. After incubation, supernatant was transferred to 96-
well plates and absorbances read at 570 and 600 nm to determine 
the metabolism of alamarBlue. The percentage of alamarBlue re-
duction was calculated as follows
  %reduction of Alamar Blue = ((O2 × A1 ) –(O1 × A2 ) / (R1 × N2 ) 
− (R2 × N1 ) ) × 100 
where O1 and O2 are the molar extinction coefficients of oxidized 
alamarBlue at wavelengths of 570 and 600 nm, respectively. R1 and 
R2 are the molar extinction coefficients of reduced alamarBlue at 
wavelengths of 570 and 600  nm, respectively. A1 and A2 are the 
observed absorbance readings for test wells at wavelengths of 570 
and 600 nm, respectively. N1 and N2 are the observed absorbance 
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Bioactive compound specificity
To determine the osteogenic specificity of bioactive compounds, a 
ranking system was developed and used. Osteogenic (RUNX2, 
OSX, ALP, and OPN), adipogenic [PPAR, fatty acid–binding 
protein 4 (FABP4), and glucose transporter type 4 (GLUT4)], and 
chondrogenic [SOX9, ACAN (aggrecan), and COL2A1 (type II collagen, 
alpha 1)] gene expression was used to determine cell differentiation 
along each lineage. Fold change gene expression after stimulation 
with each compound for 21 days was determined at 1 M concen-
tration, and fold changes were grouped and scored as follows: fold 
changes 1 to 2, 1 point; 2 to 5, 2 points; 5 to 10, 3 points; 10 to 20, 
4 points; more than 20, 5 points. Scores for each gene were recorded, 
and mean values for each category and each metabolite were calculated 
out of 5. These scores were then plotted against each other in pairs 
to determine a relative osteogenic versus chondrogenic and osteo-
genic versus adipogenic gene expression induction, providing infor-
mation about the potency and specificity of small-molecule action.
Pathway inhibition
To assess the target specificity of the glucocorticoid and mineralo-
corticoid stimulation, we used the inhibitors mifepristone (M8046, 
Sigma-Aldrich) and canrenone (SML 1497, Sigma-Aldrich), respec-
tively. Cells were seeded at 2 × 103 cells cm−2 for the specified dura-
tion of experiments (7 days for the metabolomics experiments and 
3 weeks to assess the long-term effect of mifepristone-induced glu-
cocorticoid inhibition on osteogenic marker expression). Mifepristone 
was used at 10 M, and canrenone was used at 100 M, and they 
were supplemented in the medium with every feed (twice per week) 
for the duration of each experiment.
3D OrbiSIMS
3D chemical image analysis of the sample series was performed 
using dual-beam [mode 9 (35)] TOF spectrometry, using a 30-keV 
Bi3+ primary ion source (0.3-pA target current) and a 10-keV Ar1450+ 
sputter ion source (3-nA target current). A sputter crater of 400 m 
by 400 m was etched with the central 200 m by 200 m area ana-
lyzed at a resolution of 256 pixels by 256 pixels. In each case, >3 cells 
were analyzed per sample area. Cells were also depth profiled using 
single beam Orbitrap analysis [mode 4 (35)] to acquire relatively 
high-resolution mass spectrometry data (>240,000) for the sample 
series. In this case, a 20-keV Ar3000+ primary ion source (240-pA 
target current) was used with a sputter crater of 284 m by 284 m 
with the central 200 m by 200 m area analyzed. Three analytical 
repeat areas were analyzed for each sample. A random raster func-
tion was applied throughout, as well as charge compensation with 
the application of a low-energy electron floodgun.
Single-cell force spectroscopy
Single-cell mechanics were evaluated using a nanoindentation 
device (Chiaro, Optics11, Amsterdam, NL) mounted on top of an 
inverted phase contrast microscope (Evos XL Core, Thermo Fisher 
Scientific, Paisley, UK) following a previously described approach 
(63). Human MSCs were left to incubate for 72 hours at 37°C and 
5% CO2 with the corresponding media (basal media, OGM, and 
basal media with metabolites). They were then washed once with 
Table 2. List of primary antibodies.  
Target Company Catalog number
RUNX2 Santa Cruz Biotechnology Sc-390351
Osteonectin Millipore AB1858
OPN Santa Cruz Biotechnology Sc-21742
OSX Santa Cruz Biotechnology Sc-393325
ALP Abcam Ab354
OCN Santa Cruz Biotechnology Sc-365797
Total myosin Cell Signaling Technology 3672s




Table 1. List of primers.  
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basal media only before the measurement began. All measurements 
were acquired at room temperature, keeping the measuring time 
under 90 min, to avoid changes to the cells’ mechanical properties 
that are associated with cell degeneration. A total of 35 cells from 
two biological replicates were measured for each condition. The se-
lected cantilever had a stiffness of 0.032 N m−1 and held a spherical 
tip of 3.25-m radius (serial number P190610). A tight three-by-
three map with 500-nm spacing was acquired (total of nine indenta-
tions), aiming at the cellular soma (above the nucleus). Single 
indentations were acquired at the same speed of 2 m s−1, exploiting 
the whole range of the vertical actuator, 10 m. After every experi-
ment, the probe was washed in 70% ethanol for 10 min.
The collected curves were bulk analyzed using a custom software 
programmed with Python 3 (Python Software Foundation, www.
python.org) and the Numpy/Scipy Scientific Computing Stack (64). 
Curves were first aligned using a baseline detection method based 
on the histogram of the force signal (65), and the corresponding 
indentation was calculated for each curve. To quantify the mechan-
ical properties, data were fitted with the Hertz model (66). While the 
hypothesis behind the theoretical derivation of the Hertz formula 
(isotropy, homogeneity, and pure elasticity of the sample) are fairly 
satisfied by a cellular system, it has been shown that the corresponding 
Young’s modulus can provide a robust indicator of the elasticity if 
the experimental procedure is carefully designed (67). To ensure 
consistency of the results, all the experimental parameters were kept 
constant during an experimental session for all different conditions 
(in particular, the same probe and calibration were used), and the 
results were reported, indicating changes of elasticity relative to the 
Table 3. Replicates used for each experiment. Raw data can be found at (29). 
Figure Experiment Cells from X number of donors Well replicates per group
Technical replicates per 
group
Fig. 1D and fig. S2
Nanovibration/OGM 
osteogenic gene expression 
analysis—qRT-PCR
1 4 3
Fig. 1E and fig. S3E ALP activity assay 3 2 3
Fig. 1F and fig. S3F
Off-target gene expression in 
nanovibration, OGM-
stimulated cells- qRT-PCR
3 3 (pooled) 3






Fig. 3C Nanoindentation 2 2 >100
Fig. 4A alamarBlue 2 2 3
Fig. 4B
Metabolite compound 
induction of osteogenic 
gene expression—qRT-PCR
4 3 3
Fig. 4C Off-target gene expression effects of compounds 4 3 3
Fig. 4 (D and E)
Off-/on-target gene 
expression effects of 
compounds
4 3 3
Fig. 5B Glucocorticoid receptor inhibition—qRT-PCR 1 4 2
Fig. 5C and fig. S7 3D OrbiSIMS 1 3 3
Fig. 5D Nanoindentation 2 2 >100
Fig. 5D Myosin 1 6 1
fig. S8 Actin staining 1 3 1
fig. S10A




fig. S10B Immunofluorescent staining 1 2 5
fig. S10C Colorimetric ALP activity assay 2 5 2
fig. S10D Alizarin Red staining 3 1 5
fig. S6 Effects of compound concentration—qRT-PCR 4 3 3
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control. The average absolute value for the control was also reported, 
but relative changes were typically more reliable and meaningful (67).
The calculation of the Young’s modulus of single cells based on 
nanoindentation experiments strongly depends on the indentation 
depth of the corresponding measurement. This effect is partially 
due to artifacts such as the finite thickness of the sample (68) and 
the parabolic approximation for the calculation of the Hertz formu-
la (69). Keeping the maximum indentation used in the calculation 
under ~10 to 15% of the thickness, and 20 to 25% of the radius of 
the indenter, is a rule of thumb typically used in literature (in our 
case, 600 to 700 nm would match these requirements). Neverthe-
less, for indentations lower than this threshold, a trend in the 
measured Young’s modulus as a function of the indentation depth 
appears, which is associated with the inhomogeneity of the cell (70). 
Here, we exploited this approach, trying to isolate the elasticity of 
the cortical region from the bulk of the cell. The actomyosin cortex 
is a very thin network of cytoskeletal elements that lies directly be-
neath the plasma membrane and is present in all mammalian cells 
(71). The thickness of this rigid and compact structure challenges 
current microscopy approaches, and a precise measurement is often 
complex, but existing estimates typically range between 200 and 
300  nm (72). In this work, we selected an indentation depth of 
270 nm to identify the cortical region. We called “cortical elasticity” 
the value of the Young’s modulus that was obtained by evaluating 
all the indentation curves up to this threshold. Similarly, we called 
“bulk elasticity” the value of the Young’s modulus that was calculated 
up to an indentation of 640 nm (10% of the tip diameter, the maxi-
mum to remain in the Hertzian regime).
In-cell western assays
MSCs in 24-well plates were fixed using 10% (v/v) formaldehyde for 
20 min at room temperature. Cells were then permeabilized with 
0.1% (v/v) Triton X-100 in PBS for 10 min at room temperature and 
blocked using 1% milk protein in PBS with 0.1% (v/v) Tween 20 
(PBST). Primary antibodies to target proteins diluted in blocking 
buffer (1:200) were incubated with cells overnight at 4°C with gentle 
agitation (Table 2). After incubation, cells were washed five times 
with PBST. As normalization controls, CellTag 700 stain (LI-COR) 
was diluted in blocking buffer (1:1000). To this solution, the rele-
vant secondary antibodies were added (1:2000; LI-COR). Cells were 
incubated with this solution for 1.5 hours at room temperature with 
gentle agitation, followed by five washes with PBST. Quantitative 
spectroscopic scanning and analysis were carried out using the 
LI-COR Odyssey Sa. All dyes and secondary antibodies were purchased 
from LI-COR. For analysis, internally normalized fluorescent in-
tensities were normalized against unstimulated controls to generate 
fold change fluorescent intensities.
Immunocytochemistry
Cells were fixed in 10% (v/v) formaldehyde/PBS at 4°C for 1 hour. 
Cells were permeabilized with 0.1% (v/v) Triton X-100 in PBS for 
10 min at room temperature and blocked with 1% (w/v) bovine 
serum albumin in PBS with 0.1% (v/v) Tween 20 (PBST) for 1 hour 
at room temperature. Following blocking, the relevant primary an-
tibodies (Table 2) were incubated with cells in blocking buffer over-
night at 4°C. Cells were washed three times in PBST and incubated 
with biotinylated secondary antibodies in blocking buffer (1:50; Vector 
Laboratories) for 1 hour at room temperature. Cells were again washed 
three times in PBST and incubated with fluorescein isothiocyanate– or 
Texas Red–conjugated streptavidin in blocking buffer (1:50; Vector 
Laboratories). Where appropriate, cell F-actin was labeled through 
1-hour incubation at room temperature with rhodamine-conjugated 
phalloidin (1:1000  in blocking buffer). Nuclei were stained using 
VECTASHIELD mountant with 4′,6-diamidino-2-phenylindole nu-
clear stain (Vector Laboratories).
Histological staining
Oil Red O
Cells were fixed in 10% (v/v) formaldehyde/PBS at 4°C for 1 hour, 
then washed with distilled water three times, and rinsed with 60% 
(v/v) isopropanol. Oil Red O solution was then added to the cells, 
and cells were incubated at room temperature for 15 min. Dye solu-
tion was removed, and cells were washed again with 60% (v/v) iso-
propanol, washed three times in distilled water, and imaged on an 
inverted microscope (Olympus, PA, USA) operated through Sur-
veyor software (v.9.0.1.4, Objective Imaging, Cambridge, UK). Im-
ages were processed using ImageJ [v.1.50g, National Institutes of 
Health (NIH), USA].
Alizarin Red staining
Cells were fixed in 10% (v/v) formaldehyde/PBS at 4°C for 1 hour. 
After washing with PBS, fixed cells were stained with 2% (w/v) Alizarin 
Red solution (pH 4.1 to pH 4.3) for 15 min at room temperature. After 
staining, cells were washed in deionized water and imaged on an 
inverted microscope (Olympus, Pennsylvania, USA), operated through 
Surveyor software (v.9.0.1.4, Objective Imaging, Cambridge, UK). 
Images were processed using ImageJ (v.1.50g, NIH, USA).
Statistics
Statistical analysis of the effects of nanovibration and OGM on os-
teogenic gene expression through qRT-PCR was performed by one-
way analysis of variance (ANOVA) with Holm-Sidak’s multiple 
comparison test. Data are means ± SEM or means ± SD. Statistical 
analysis of off-target gene expression induction by nanovibration or 
OGM was conducted through Kruskal-Wallis with Dunn’s multiple 
comparison test. ALP assay data were statistically analyzed using 
Kruskal-Wallis with Dunn’s multiple comparison test, as was the 
bioactive small molecule–mediated induction of osteogenic genes. 
alamarBlue experiments were statistically compared by one-way 
ANOVA with Geisser-Greenhouse correction and Tukey multiple 
comparison test. All statistical analysis was performed using GraphPad 
Prism software (v8.0.0; GraphPad Software Inc.)
Please note that we denote replicates as follows: number of do-
nors that were used for the particular experiment (i.e., experimental 
repeats) = d, replicates (i.e., number of wells) = r, and technical rep-
licates for quantitative PCR etc. to test pipetting error = t (if used). 
Full information is given in Table  3. Please see Supplementary 
Methods for further details.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/9/eabb7921/DC1
View/request a protocol for this paper from Bio-protocol.
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